Skip to main content

Table 4 Effects of different MTNR1B rs10830963 genotypes in T2DM patients on clinical traits determined before and after nateglinide treatment

From: Evaluation of the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients

Parameters CC(n = 26) CG(n = 26) + GG(n = 8) P value
N (male/female) 26 (16/10) 34(20/14) 0.902Δ
FPG (mmol/L)
 Before 10.73 ± 2.05 10.81 ± 1.92 0.877
 After 6.98 ± 1.35 7.94 ± 1.23 0.006*
 DV − 3.75 ± 1.68 − 2.87 ± 1.32 0.027*
PPG (mmol/L)
 Before 14.51 ± 4.31 13.04 ± 4.72 0.220
 After 9.34 ± 3.24 9.27 ± 3.49 0.937
 DV − 5.17 ± 4.08 − 3.77 ± 3.19 0.141#
FINS (mU/L)
 Before 8.82 ± 6.81 7.80 ± 4.20 0.478
 After 10.18 ± 6.60 9.32 ± 3.64 0.522
 DV 1.36 ± 4.10 1.84 ± 3.80 0.641
PINS (mU/L)
 Before 31.42 ± 20.47 27.47 ± 16.43 0.410
 After 48.41 ± 19.78 37.13 ± 20.87 0.038*
 DV 16.99 ± 17.82 9.66 ± 19.37 0.138
HOMA-IR
 Before 4.48 ± 2.88 3.24 ± 1.73 0.066
 After 3.39 ± 2.12 2.43 ± 1.18 0.072
 DV − 0.89 ± 1.93 − 0.79 ± 1.31 0.704
HOMA-β
 Before 27.75 ± 16.03 24.08 ± 17.32 0.405
 After 68.62 ± 45.21 49.21 ± 24.36 0.037*
 DV 40.87 ± 23.52 25.13 ± 19.21 0.006*
HbA1c (%)
 Before 9.79 ± 1.86 9.15 ± 2.26 0.246#
 After 7.00 ± 0.84 7.01 ± 1.05 0.968
 DV − 2.79 ± 1.53 − 2.14 ± 1.74 0.137
TG (mmol/L)
 Before 2.46 ± 1.96 2.31 ± 1.90 0.766
 After 2.21 ± 1.91 1.79 ± 1.23 0.306
 DV − 0.25 ± 1.95 − 0.52 ± 1.58 0.096#
TC (mmol/L)
 Before 5.27 ± 1.69 5.22 ± 1.15 0.892#
 After 4.84 ± 1.12 4.89 ± 1.37 0.880#
 DV − 0.43 ± 1.53 − 0.33 ± 1.09 0.769#
HDL-c (mmol/L)
 Before 1.42 ± 0.51 1.47 ± 0.47 0.695#
 After 1.35 ± 0.55 1.43 ± 0.51 0.563#
 DV − 0.07 ± 0.68 − 0.04 ± 0.46 0.839
LDL-c (mmol/L)
 Before 3.28 ± 1.19 3.18 ± 1.05 0.731#
 After 3.19 ± 1.20 3.11 ± 1.07 0.786
 DV − 0.09 ± 1.26 − 0.07 ± 1.08 0.948
  1. BMI body mass index, WHR waist to hip ratio, FPG fasting plasma glucose, PPG postprandial plasma glucose, FINS fasting serum insulin, PINS postprandial serum insulin, HOMA-IR homeostasis model assessment for insulin resistance, HOMA-β Homeostasis model assessment for islet β cell function, HbA1c hemoglobin A1c, TG triglyceride, TC total cholesterol, HDL-c high-density lipoprotein-cholesterol, LDL-c low-density lipoprotein-cholesterol, DV differential values (post-administration minus pre-administration)
  2. Data are given as (mean ± SD). ΔP values are determined by the Pearson chi-square test. #P values are determined by the Kruskal–Wallis test. *P < 0.05